Health experts have declined requests for expanded prostate cancer testing for men. The UK National Screening Committee has raised concerns that routine screenings may lead to unnecessary surgeries and has decided against increasing testing for high-risk groups such as Black men and those with a family history of the disease.
Despite advocacy from Olympic champion Sir Chris Hoy, who is battling terminal prostate cancer, and support from various organizations and politicians, the UKNSC has determined that current blood tests are not sufficiently reliable and may result in overtreatment of benign tumors that would not have posed a threat to men.
The committee’s analysis indicated that widespread screening would not significantly reduce overall mortality rates when considering all factors but did recommend targeted screening for a limited number of men with the BRCA gene.
Professor Sir Mike Richards, chair of the UKNSC, acknowledged the push for prostate cancer screening and its potential to reduce cancer-related deaths to some extent. However, he emphasized that screening’s impact on overall survival remains inconclusive, noting the slow progression of prostate cancer in many men and the challenge of distinguishing harmful from harmless forms of the disease.
Prostate cancer has become the most prevalent cancer in the UK partly due to increased awareness and screening. Men can request a blood test from their GP if they experience symptoms, although the reliability of the PSA test has been questioned.
The UKNSC highlighted at a media briefing that while screening could lower prostate cancer deaths, it might also lead to premature deaths from other causes by causing overdiagnosis and overtreatment. Overzealous treatment like prostate removal can have severe consequences, including impotence and urinary incontinence, affecting the quality and length of life.
Experts emphasized the challenges of determining the necessity of treatment for diagnosed prostate cancer, citing the difficulty in distinguishing between aggressive and non-aggressive cases. The committee received backlash for initially rejecting widespread screening and later narrowing targeted screening to men with specific genetic variants and family history.
Less than 5% of prostate cancer cases are associated with genetic risk factors, with the government expected to review and likely adopt the committee’s guidance.
In response to the decision, health authorities and organizations like Cancer Research UK and Prostate Cancer UK expressed disappointment, emphasizing the potential benefits of a broader screening program but acknowledging the current lack of evidence to support it.
As the government considers the UKNSC’s recommendation, the debate surrounding prostate cancer screening continues, with stakeholders advocating for a balance between the benefits and risks of widespread testing.
